ArticleRisk management and healthcare policy2024

Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.

Lidan Yi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.